NasdaqGS:DYNBiotechs
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?
Dyne Therapeutics (DYN) has moved squarely into focus after it appointed veteran biopharmaceutical executive Barry E. Greene as an independent board member and expanded its loan facility with Hercules Capital to support upcoming milestones.
See our latest analysis for Dyne Therapeutics.
For context, Dyne Therapeutics shares trade at $20.33, with a 30-day share price return of 17.04% and a year-to-date share price return of 9.89%. The 1-year total shareholder return of 95.11% reflects strong...